# Randomized Phase 2 Study of 3 Therapeutic Modalities in PS 2/3 Patients With NSCLC Stage IIIB/IV

> **NCT00198393** · PHASE2 · COMPLETED · sponsor: **Intergroupe Francophone de Cancerologie Thoracique** · enrollment: 126 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Gefitinib
- **DRUG:** gemcitabine
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00198393
- **Lead sponsor:** Intergroupe Francophone de Cancerologie Thoracique
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2008-06
- **Final completion:** 2008-12
- **Target enrollment:** 126 (ACTUAL)
- **Last updated:** 2010-04-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00198393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00198393, "Randomized Phase 2 Study of 3 Therapeutic Modalities in PS 2/3 Patients With NSCLC Stage IIIB/IV". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00198393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*